Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 4Phase 1/2 3Phase 2 2

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Neoplasm Metastasis 1Leukemia 1Head and Neck Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Solutions × Clear all
NCT02031055 2024-09-05

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
8 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04771390 2021-08-25

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

Bayer

Phase 1 Completed
52 enrolled
Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04675021 2021-01-26

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

AstraZeneca

Phase 1 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

NCT01314599 2015-11-05

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

PharmaMar

Phase 1 Completed
45 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡